



FORM PTO-1449 <b>INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 1488.130000B/EKS/EJH/M-K	APPLICATION NO. 10/648,786
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP <del>1644</del> 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
CK ↓	AA1	4,002,531	01/11/1977	Royer	X	X	01/22/1976
	AB1	4,946,778	08/07/1990	Ladner et al.			01/19/1989
	AC1	5,349,053	09/20/1994	Landolfi			06/10/1993
	AD1	5,447,851	09/05/1995	Beutler et al.			04/02/1992
	AE1	5,478,925	12/26/1995	Wallach et al.			08/07/1992
	AF1	5,530,101	06/25/1996	Queen et al.			12/19/1990
CK	AG1	5,565,332	10/15/1996	Hoogenboom et al.	X	X	09/23/1992
	AH1	5,807,715	09/15/1998	Morrison et al.			06/27/1994
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
CK ↓	AL1	WO 91/06570	05/16/1991	WIPO	X	X	Yes No
	AM1	WO 91/09967	07/11/1991	WIPO			Yes No
	AN1	CA 2,045,869	12/29/1991	Canada			Yes No
	AO1	EP 0 239 400 B1	08/03/1994	Europe			Yes No
CK	AP1	WO 95/06058	03/02/1995	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
CK	AR	1	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95," <i>Science</i> 24:990-992, American Association for the Advancement of Science (November 1996)
CK	AS	1	Delgado et al., "The Uses and Properties of PEG-Linked Proteins," <i>Crit. Rev. Thera. Drug Carrier Sys.</i> 9:249-304, Begell House (1992)
CK	AT	1	Goodman, J.W., "Immunogens & Antigens," in <i>Basic &amp; Clinical Immunology</i> , Stites et al., eds., Appleton & Lange, Norwalk, CT, pp. 20-27 (1988)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449				ATTY. DOCKET NO. 1488.130000B/EKS/EJH/M-K		APPLICATION NO. 10/648,786	
INFORMATION DISCLOSURE STATEMENT				APPLICANT Ni et al.			
				FILING DATE August 27, 2003		GROUP 1646	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
CK	AL2	EP 0 401 384 B1	03/13/1996	Europe	X	X	Yes No
CK	AM2	WO 97/01633	01/16/1997	WIPO			Yes No
CK	AN2	WO 98/30693	07/16/1998	WIPO			Yes No
CK	AO2	EP 0 857 782 A2	08/12/1998	Europe			Yes No
CK	AP2	WO 98/41629	09/24/1998	WIPO			Yes No
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
CK	AR	2	Huston et al., "Protein Engineering of Single-Chain Fv Analogs and Fusion Proteins," <i>Methods in Enzymology</i> 203:46-88, Academic Press (1991)				
CK	AS	2	Morpurgo et al., "Covalent Modification of Mushroom Tyrosinase with Different Amphiphilic Polymers for Pharmaceutical and Biocatalysis Applications," <i>Appl. Biochem. Biotechnol.</i> 56:59-72, Humana Press (January 1996)				
CK	AT	2	Morrison, S.L. "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> 229:1202-1207, American Association for the Advancement of Science (1985)				
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.130000B/EKS/EJH/M-K	APPLICATION NO. 10/648,786
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP <del>1644</del> 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
CK	AL3	WO 99/02653	01/21/1999	WIPO	X		Yes No
CK	AM3	WO 99/11791	03/11/1999	WIPO			Yes No
CK	AN3	WO 99/37684	07/29/1999	WIPO			Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
CK	AR	3	Pan, G. et al., "The Receptor for the Cytotoxic Ligand Trail," <i>Science</i> 276:111-113, American Association for Advancement of Science (April 1997)				
CK	AS	3	Roguska et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing," <i>Proc. Natl. Acad. Sci. USA</i> 91:969-973, National Academy of Science (1994)				
CK	AT	3	Ruf et al., "Structure and Expression of the Gene Coding for the Alpha-Subunit of DNA-Dependent RNA Polymerase from the Chloroplast Genome of Zea Mays," <i>Nucl. Acids Res.</i> 16:5741-5754, IRL Press (1988)				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.130000B/EKS/EJH/M-K	APPLICATION NO. 10/648,786
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP <del>1614</del> 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
CK	AR	<u>4</u>	Wiley, S.R. et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis," <i>Immunity</i> 3:673-682, Cell Press (1995)
CK	AS	<u>4</u>	Database, EMBL Nucleic Acid DB EBI, Accession No. AA100865, Hillier et al., (October 1996)
CK	AT	<u>4</u>	GenBank Accession No. W65310, zd33e01.r1 Soares fetal heart NbHH19W Homo Sapiens cDNA clone 342456 5' similar to contains Alu repetitive element, NCBI National Library of Medicine Database, Bethesda, MD, USA, accessed 1/8/99, (October 1996)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.130000B/EKS/EJH/M-K	APPLICATION NO. 10/648,786
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP <del>1614</del> 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
CK	AR	<u>5</u>	NCBI Entrez, GenBank Report, Accession No. AA150849, from Hillier, L., et al. (December 1996)
CK	AS	<u>5</u>	NCBI Entrez, GenBank Report, Accession No. AA102745, from Hillier, L., et al. (October 1996)
CK	AT	<u>5</u>	NCBI Entrez, GenBank Report, Accession No. AA102746, from Hillier, L., et al. (October 1996)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 1488.130000B/EKS/EJH/M-K	APPLICATION NO. 10/648,786
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP <del>1614</del> 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	6	NCBI Entrez, GenBank Report, Accession No. AA102383, from Hillier, L., et al. (October 1996)
	AS		
	AT		

EXAMINER	/Claire Kaufman/	DATE CONSIDERED	12/14/2006
----------	------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 1488.130000B/EKS/EJH/M-K	APPLICATION NO. 10/648,786
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP 1614 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
CK	AI1	4,179,337	12/18/1979	Davis et al.			07/28/1977
CK	AJ1	6,342,363	01/29/2002	Ni et al.			01/27/1998
CK	AK1	6,433,147	08/13/2002	Ni et al.			05/05/2000

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
CK	AO3	WO 98/32856	07/30/1998	WIPO			Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
CK	AS	6	Delgado, C., et al., "Quantitative analysis of polyethylene glycol (PEG) in PEG-modified proteins/cytokines by aqueous two-phase systems," <i>J. Biochem. Biophys. Methods</i> 29:237-250, Elsevier Science B.V. (1994).
CK	AT	6	Dillman, R.O., "Monoclonal Antibodies for Treating Cancer," <i>Ann. Internal Med.</i> 111:592-603, American College of Physicians (1989).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>	ATTY. DOCKET NO. 1488.130000B/EKS/EJH/M-K	APPLICATION NO. 10/648,786
	APPLICANT Ni et al.	
	FILING DATE August 27, 2003	GROUP <del>1614</del> 1646


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
CK	AA2	6,461,823	10/08/2002	Ni et al.			11/24/1999
	AB2	2003/0036168 A1	02/20/2003	Ni et al.			08/23/2002
	AC2	2003/0073187 A1	04/17/2003	Ni et al.			08/23/2002
CK	AD2	2003/0108516 A1	06/12/2003	Ni et al.			06/21/2002
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
CK	AR	<u>2</u>	NCBI Genbank Accession No. U90875, Pan, G., et al., (April 1997).
CK	AS	<u>2</u>	Pending Non-Provisional U.S. Patent Application No. 09/912,292, filed July 26, 2001, NOT PUBLISHED: pages 1-75 (pages 1 + 2 partially redacted); portion of Table 2; and SEQ ID Nos: 7950 and 52011
	AT		

EXAMINER	/Claire Kaufman/	DATE CONSIDERED	12/14/2006
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			





FORM PTO-849

SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1488.130000B/EKS/EJH/M-KAPPLICATION NO.  
10/648,786FIRST NAMED INVENTOR  
Ni *et al.*FILING DATE  
August 27, 2003ART UNIT  
~~1614~~ 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
CK	AT	I	Chantry, D., "Tumour necrosis factor antagonists," <i>Emerging Drugs</i> 4:5-13, Ashley Publications Ltd (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1488.130000B/EKS/EJH/M-KAPPLICATION NO.  
10/648,786FIRST NAMED INVENTOR  
Ni *et al.*FILING DATE  
August 27, 2003ART UNIT  
~~1614~~ 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	8	Kim, K., <i>et al.</i> , "Molecular determinants of response to TRAIL combined with chemotherapy in killing of normal cancer cells," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> 40:486, 90 <sup>th</sup> Annual Meeting of the American Association for Cancer Research (April 1999)
CK	AS	8	Marsters, S.A., <i>et al.</i> , "Control of Apoptosis Signaling by Apo2 Ligand," <i>Recent Progress in Hormone Research</i> 54:225-234, The Endocrine Society (1999)
CK	AT	8	International Search Report for International Application No. PCT/US 98/01464, European Patent Office, Netherlands, mailed on June 17, 1998

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1488.130000B/EKS/EJH/M-KAPPLICATION NO.  
10/648,786FIRST NAMED INVENTOR  
Ni et al.FILING DATE  
August 27, 2003ART UNIT 1646  
~~1014~~

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

CK	AR	9	Supplementary Partial European Search Report for European Application No. EP 00 93 2061, European Patent Office, Netherlands, completed on August 23, 2004
	AS		
	AT		

EXAMINER /Claire Kaufman/

DATE CONSIDERED 12/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SEP 08 2005  
TRADEMARK OFFICE

[illegible][illegible]

436556 1.DOC

Examiner Signature	/Claire Kaufman/	Date Considered	12/14/2006
-----------------------	------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \* See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/08B (07-05)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/648,786
		Filing Date	August 27, 2003
		First Named Inventor	Jian Ni
		Art Unit	<del>1614</del> 1646
		Examiner Name	Kaufman, Claire M.
Sheet	2 of 2	Attorney Docket Number	1488.130000B/EKS/EJH/

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
CK	AS9	Lerner, R.A., "Antibodies of Predetermined Specificity in Biology and Medicine," <i>Adv. Immunol.</i> 36:1-44, Academic Press, Inc. (1984)	
CK	AT9	NCBI Entrez, GenBank Report, Accession No. AA639619, Strausberg, R., National Center for Biotechnology Information (1997)	
CK	AR10	Strader, C.D., <i>et al.</i> , "Structural basis of $\beta$ -adrenergic receptor function," <i>FASEB J.</i> 3:1825-1832, Federation of American Societies for Experimental Biology (1989)	
CK	AS10	Walczak, H., <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> 16:5386-5397, Oxford University Press (1997)	

436563\_1.DOC

Examiner Signature	/Claire Kaufman/	Date Considered	12/14/2006
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.